Acurx Pharmaceuticals, Inc. (ACXP) Key Statistics & Financial Ratios

Acurx Pharmaceuticals, Inc. (ACXP) — Price $1.38 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Acurx Pharmaceuticals, Inc. (ACXP). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections.

Stock Data

Price$1.38
Market Cap$6M
Enterprise Value-$4.7M
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-0.39
Price / Book0.72
P/S0.00
EV/EBITDA0.63
EV/Sales0.00
EV/FCF0.76
P/FCF-0.96
Earnings Yield-127.70%
FCF Yield-104.25%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity-124.74%
Return on Assets-68.33%
Return on Invested Capital-94.08%
Return on Capital Employed-94.08%

Financial Health

Current Ratio3.88
Quick Ratio3.88
Cash Ratio3.76
Debt / Equity0.00
Debt / Assets0.00%
Net Debt / EBITDA1.41
Interest Coverage0.00

Per-Share Data

Revenue per share0.00
Book Value per share1.91
Cash per share2.50
FCF per share-1.45
Tangible Book Value per share1.91
Dividend per share0.00

Related companies: ADIL · APRE · APVO · BCDA · BCLI · CELZ · GLTO

Explore sector: Healthcare · Biotechnology

More sections of ACXP: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks